SEARCH

SEARCH BY CITATION

References

  • 1
    Liau LM,Black KL,Prins RM,Sykes SN,DiPatre PL,Cloughesy TF,Becker DP,Bronstein JM. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999; 90: 111524.
  • 2
    Heimberger AB,Crotty LE,Archer GE,McLendon RE,Friedman A,Dranoff G,Bigner DD,Sampson JH. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 2000; 103: 1625.
  • 3
    Akasaki Y,Kikuchi T,Homma S,Abe T,Kofe D,Ohno T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 2001; 24: 10613.
  • 4
    Aoki H,Mizuno M,Natsume A,Tsugawa T,Tsujimura K,Takahashi T,Yoshida J. Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 2001; 50: 4638.
  • 5
    Kikuchi T,Akasaki Y,Abe T,Ohno T. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother 2002; 51: 42430.
  • 6
    Ni HT,Spellman SR,Jean WC,Hall WA,Low WC. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 2001; 51: 19.
  • 7
    Insug O,Ku G,Ertl HC,Blaszczyk-Thurin M. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002; 22: 61321.
  • 8
    Jouanneau E,Poujol D,Gulia S,Le Mercier I,Blay JY,Belin MF,Puisieux I. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother 2006; 55: 25467.
  • 9
    Pellegatta S,Poliani PL,Corno D,Grisoli M,Cusimano M,Ubiali F,Baggi F,Bruzzone MG,Finocchiaro G. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 2006; 28: 52731.
  • 10
    Yu JS,Wheeler CJ,Zeltzer PM,Ying H,Finger DN,Lee PK,Yong WH,Incardona F,Thompson RC,Riedinger MS,Zhang W,Prins RM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61: 8427.
  • 11
    Yu JS,Liu G,Ying H,Yong WH,Black KL,Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64: 49739.
  • 12
    Yamanaka R,Homma J,Yajima N,Tsuchiya N,Sano M,Kobayashi T,Yoshida S,Abe T,Narita M,Takahashi M,Tanaka R. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11: 41607.
  • 13
    Liau LM,Prins RM,Kiertscher SM,Odesa SK,Kremen TJ,Giovannone AJ,Lin JW,Chute DJ,Mischel PS,Cloughesy TF,Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005; 11: 551525.
  • 14
    Rutkowski S,De Vleeschouwer S,Kaempgen E,Wolff JE,Kuhl J,Demaerel P,Warmuth-Metz M,Flamen P,Van Calenbergh F,Plets C,Sorensen N,Opitz A, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004; 91: 165662.
  • 15
    Yamanaka R,Abe T,Yajima N,Tsuchiya N,Homma J,Kobayashi T,Narita M,Takahashi M,Tanaka R. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003; 89: 11729.
  • 16
    Rosenberg SA,Yang JC,Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 90915.
  • 17
    Bodmer S,Huber D,Heid I,Fontana A. Human glioblastoma cell derived transforming growth factor-β 2: evidence for secretion of both high and low molecular weight biologically active forms. J Neuroimmunol 1991; 34: 3342.
  • 18
    Hishii M,Nitta T,Ishida H,Ebato M,Kurosu A,Yagita H,Sato K,Okumura K. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 1995; 37: 11606 (discussion 66–7).
  • 19
    Sawamura Y,Diserens AC,de Tribolet N. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J Neurooncol 1990; 9: 12530.
  • 20
    Wiendl H,Mitsdoerffer M,Hofmeister V,Wischhusen J,Bornemann A,Meyermann R,Weiss EH,Melms A,Weller M. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002; 168: 477280.
  • 21
    Saas P;Walker PR,Hahne M,Quiquerez AL,Schnuriger V,Perrin G,French L,Van Meir EG,de Tribolet N,Tschopp J,Dietrich PY. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 11738.
  • 22
    Fecci PE,Sweeney AE,Grossi PM,Nair SK,Learn CA,Mitchell DA,Cui X,Cummings TJ,Bigner DD,Gilboa E,Sampson JH. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 2006; 12 (14 Part 1): 4294305.
  • 23
    Fecci PE,Mitchell DA,Whitesides JF,Xie W,Friedman AH,Archer GE,Herndon JE,IIBigner DD,Dranoff G,Sampson JH. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66: 3294302.
  • 24
    El Andaloussi A,Han Y,Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006; 105: 4307.
  • 25
    Grauer OM,Nierkens S,Bennink E,Toonen LW,Boon L,Wesseling P,Sutmuller RP,Adema GJ. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121: 95105.
  • 26
    Zhou Y,Bosch ML,Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 2002; 25: 289303.
  • 27
    Vari F,Hart DN. Loading DCs with Ag. Cytotherapy 2004; 6: 11121.
  • 28
    Sahin U,Koslowski M,Tureci O,Eberle T,Zwick C,Romeike B,Moringlane JR,Schwechheimer K,Feiden W,Pfreundschuh M. Expression of cancer testis genes in human brain tumors. Clin Cancer Res 2000; 6: 391622.
  • 29
    Scarcella DL,Chow CW,Gonzales MF,Economou C,Brasseur F,Ashley DM. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 1999; 5: 33541.
  • 30
    Chi DD,Merchant RE,Rand R,Conrad AJ,Garrison D,Turner R,Morton DL,Hoon DS. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997; 150: 214352.
  • 31
    Liu G,Ying H,Zeng G,Wheeler CJ,Black KL,Yu JS. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 2004; 64: 49806.
  • 32
    Wang RF,Appella E,Kawakami Y,Kang X,Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184: 220716.
  • 33
    Bloom MB,Perry-Lalley D,Robbins PF,Li Y,el-Gamil M,Rosenberg SA,Yang JC. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185: 4539.
  • 34
    Schreurs MW,Eggert AA,de Boer AJ,Vissers JL,van Hall T,Offringa R,Figdor CG,Adema GJ. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 2000; 60: 69957001.
  • 35
    Prins RM,Odesa SK,Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003; 63: 848791.
  • 36
    InSug O,Blaszczyk-Thurin M,Shen CT,Ertl HC. A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Ther 2003; 10: 67888.
  • 37
    Liu G,Khong HT,Wheeler CJ,Yu JS,Black KL,Ying H. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother 2003; 26: 30112.
  • 38
    Fields RC,Shimizu K,Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 94827.
  • 39
    Fischer K,Andreesen R,Mackensen A. An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity. J Immunol Methods 2002; 259: 15969.
  • 40
    Parkhurst MR,Fitzgerald EB,Southwood S,Sette A,Rosenberg SA,Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998; 58: 4895901.
  • 41
    Kaplan JM,Yu Q,Piraino ST,Pennington SE,Shankara S,Woodworth LA,Roberts BL. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999; 163: 699707.
  • 42
    Bronte V,Apolloni E,Ronca R,Zamboni P,Overwijk WW,Surman DR,Restifo NP,Zanovello P. Genetic vaccination with “self” tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000; 60: 2538.
  • 43
    Goldszmid RS,Idoyaga J,Bravo AI,Steinman R,Mordoh J,Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 2003; 171: 59407.
  • 44
    Prasad SJ,Farrand KJ,Matthews SA,Chang JH,McHugh RS,Ronchese F. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol 2005; 174: 908.
  • 45
    Marzo AL,Kinnear BF,Lake RA,Frelinger JJ,Collins EJ,Robinson BW,Scott B. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 2000; 165: 604755.
  • 46
    Hung K,Hayashi R,Lafond-Walker A,Lowenstein C,Pardoll D,Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 235768.
  • 47
    Bohm W,Thoma S,Leithauser F,Moller P,Schirmbeck R,Reimann J. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J Immunol 1998; 161: 897908.
  • 48
    Stohlman SA,Bergmann CC,Lin MT,Cua DJ,Hinton DR. CTL effector function within the central nervous system requires CD4+ T cells. J Immunol 1998; 160: 2896904.
  • 49
    Yamazaki S,Iyoda T,Tarbell K,Olson K,Velinzon K,Inaba K,Steinman RM. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198: 23547.
  • 50
    Banerjee DK,Dhodapkar MV,Matayeva E,Steinman RM,Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006; 108: 265561.
  • 51
    Oldenhove G,de Heusch M,Urbain-Vansanten G,Urbain J,Maliszewski C,Leo O,Moser M. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med 2003; 198: 25966.
  • 52
    Van Meirvenne S,Dullaers M,Heirman C,Straetman L,Michiels A,Thielemans K. In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells. Mol Ther 2005; 12: 92232.
  • 53
    Onizuka S,Tawara I,Shimizu J,Sakaguchi S,Fujita T,Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 1999; 59: 312833.
  • 54
    Sutmuller RP,van Duivenvoorde LM,van Elsas A,Schumacher TN,Wildenberg ME,Allison JP,Toes RE,Offringa R,Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 82332.
  • 55
    El Andaloussi A,Lesniak MS. An increase in CD4+CD25+ FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 2006; 8: 23443.
  • 56
    El Andaloussi A,Lesniak MS. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 2007; 83: 14552.
  • 57
    Nair S,Boczkowski D,Fassnacht M,Pisetsky D,Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007; 67: 37180.
  • 58
    Ghiringhelli F,Larmonier N,Schmitt E,Parcellier A,Cathelin D,Garrido C,Chauffert B,Solary E,Bonnotte B,Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34: 33644.